One year of daily Daybue (trofinetide) treatment led to improvements in behaviors such as nonverbal communication, alertness, and social interaction and connectedness among children and adults with Rett syndrome. That’s according to published interim data from Acadia Pharmaceuticals‘ Phase 4 LOTUS study that assessed the safety and effectiveness of the approved oral therapy in 227 […] The post Daybue shows real-world benefits for Rett syndrome patients: Study appeared first on Rett Synd...
